Rafael Bruck graduated Medicine in the Sackler Faculty of Medicine at Tel Aviv University, Israel and completed his residency in Internal Medicine in 1986 and his fellowship in Gastrointestinal and Liver Diseases in 1989. During 1989-1991 he did a research fellowship in the Liver Center, Yale University School of Medicine, New Haven, USA. During and after this period Dr. Bruck published several papers about bile physiology in leading journals. Later, upon returning to Israel he continued his basic research and studied prevention of liver damage in various rat models of acute and chronic toxic and immune-mediated liver injury. Dr. Bruck Participated in numerous clinical studies, many as PI, mainly on the treatment of patients with hepatitis C, over 20 years, at first using interferon-based therapies and later with the new DAAs. Dr. Bruck participated in phase II and III clinical trials with many DAAs such as Simeprevir, Daclatasvir and Asunaprevir, Abbvie 3D, Elbasvir and Grazoprevir and Abbvie's new G/P (ENDURNCE 1) compound. Dr. Bruck also participates in clinical studies testing new compounds aimed at the treatment of NASH. Currently, Prof. Bruck is the Deputy of the head of the GI and Liver Institute in Tel Aviv Medical Center in Israel. Rafael Bruck graduated Medicine in the Sackler Faculty of Medicine at Tel Aviv University, Israel and completed his residency in Internal Medicine in 1986 and his fellowship in Gastrointestinal and Liver Diseases in 1989. During 1989-1991 he did a research fellowship in the Liver Center, Yale University School of Medicine, New Haven, USA. During and after this period Dr. Bruck published several papers about bile physiology in leading journals. Later, upon returning to Israel he continued his basic research and studied prevention of liver damage in various rat models of acute and chronic toxic and immune-mediated liver injury. Dr. Bruck Participated in numerous clinical studies, many as PI, mainly on the treatment of patients with hepatitis C, over 20 years, at first using interferon-based therapies and later with the new DAAs. Dr. Bruck participated in phase II and III clinical trials with many DAAs such as Simeprevir, Daclatasvir and Asunaprevir, Abbvie 3D, Elbasvir and Grazoprevir and Abbvie's new G/P (ENDURNCE 1) compound. Dr. Bruck also participates in clinical studies testing new compounds aimed at the treatment of NASH. Currently, Prof. Bruck is the Deputy of the head of the GI and Liver Institute in Tel Aviv Medical Center in Israel.

Gastroenterology